An observational study in Ankylosing Spondylitis, Autoimmune Disease and Crohn Disease, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Spondylitis, Ankylosing with a site in United States — 10 open to participants now, 13 under way, none of them phase 3. Spondylitis, Ankylosing · United States.
Among the 87 studies in Spondylitis, Ankylosing with a site in United States, this one is the 22nd largest by planned enrollment of the 28 observational ones that give a count, is the only one that started in 2022, is one of 28 observational ones, reaches primary completion later than 6 of the 11 other live ones, and was the 72nd registered.
535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.
Browse Spondylitis, Ankylosing studies →10 of the 87 studies in Spondylitis, Ankylosing with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18+
University of Central Florida · Sites in United States
Ages 18–65
Brain Inflammation Collaborative · Sites in United States
Ages 2+ · Healthy volunteers
AndHealth · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 19 · Phase 3 25 · Phase 4 3
First in 1995; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is below the median of 201 across 216 observational studies indexed under Spondylitis, Ankylosing.
Median enrollment 223 across the 59 interventional studies, 445 across the 28 observational. Of the 68 that completed or were terminated, 40 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 87 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 1 study filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
1 of the studies in Spondylitis, Ankylosing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04751396M.D. Anderson Cancer CenterTesting of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors | 2027-02-02 |
Add it to your calendar (.ics) → With an account.
Among the 87 studies in Spondylitis, Ankylosing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.
PRIMARY OBJECTIVES:
I. To evaluate the acceptability (e.g., ease of use, design, accessibility, content) of the educational tool that will be developed for patients with melanoma and pre-existing autoimmune conditions considering or undergoing treatment with immune checkpoint inhibitors.
II. To test the usability in real world-settings of the educational tool (to be developed) and evaluate feasibility of patient recruitment (i.e., ability to identify enough patients and consent at least 50% of the identified patients) in a pilot study.
OUTLINE:
PART A: Participants navigate the educational tool over 30-45 minutes then participate in an interview about their thoughts and opinions about the content, ease of use, and format of the tool over 45 minutes.
PART B: 2 group of participants will be evaluated sequentially (Participants in group II will be enrolled after all the participants in group I have been assessed).
GROUP I: Patients receive standard educational information during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
GROUP II: Patients navigate educational tool over 20 minutes during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
Patients with melanoma or pre-existing autoimmune disease and clinicians
Inclusion Criteria:
Diagnosis of pre-existing disease
Inflammatory bowel disease
Rheumatoid arthritis
Systemic lupus erythematosus
Psoriasis
Spondyloarthropathies
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants navigate the educational tool over 30-45 minutes then participate in an interview about their thoughts and opinions about the content, ease of use, and format of the tool over 45 minutes.
Other: Educational Intervention · Other: Interview
Patients receive standard educational information during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
Other: Best Practice · Other: Questionnaire Administration · Other: Survey Administration
Patients navigate educational tool over 20 minutes during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
Other: Educational Intervention · Other: Questionnaire Administration · Other: Survey Administration
Receive standard educational information
Also known as: standard of care, standard therapy
Navigate educational tool
Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Participate in interview
Complete questionnaire
Complete surveys
Decisional conflict scale
The scale will be used to assess personal perceptions of 1) uncertainty in choosing among options; 2) modifiable factors contributing to uncertainty, such as feeling uninformed, and 3) feeling that the choice is values-based and likely to be implemented.
Time frame: Up to 4 years
Knowledge
Will be assessed using a questionnaire developed by the research team covering various content areas, including general information about immune checkpoint inhibitors and the associated adverse effects and benefits of the treatments.
Time frame: Up to 3 months
Acceptability
A standard assessment questionnaire will be used to obtain users' ratings of various features of the educational tool, including ease of use, presentation, usefulness and satisfaction. The items in the questionnaire come from the Ottawa Acceptability Measures.
Time frame: Immediately after the clinical encounter
Usability
A standard assessment questionnaire will be used to obtain users' ratings of various features of the educational tool, including ease of use, presentation, usefulness and satisfaction. The items in the questionnaire come from the Ottawa Acceptability Measures.
Time frame: Immediately after the clinical encounter
Depression
Will be assessed using the Depression and Anxiety Stress Scale (DASS). The DASS is a 21-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress. The Depression scale assesses dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest/involvement, anhedonia, and inertia
Time frame: Up to 3 months
Anxiety
Will be assessed using the DASS. The DASS is a 21-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress. The Anxiety scale assesses autonomic arousal, skeletal muscle effects, situational anxiety, and subjective experience of anxious affect.
Time frame: Up to 3 months
Stress
Will be assessed using the DASS. The DASS is a 21-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress. The Stress scale is sensitive to levels of chronic non-specific arousal. It assesses difficulty relaxing, nervous arousal, and being easily upset/agitated, irritable/over-reactive and impatient.
Time frame: Up to 3 months
CollaboRATE measure
The CollaboRATE questions ask about the effort made to help patients understand their health issues, listen to what matters most to them, and include what matters most to them in choosing what to do next.
Time frame: Immediately after the clinical encounter
Shared decision-making process survey
This instrument measures the extent to which health care providers engage patients in shared decision making. Items are focused on four specific behaviors that are critical for shared decision making -discussion of options, pros, cons and preferences.
Time frame: Immediately after the clinical encounter
Patient's perception of usefulness of the tool
Will use the Preparation for Decision Making Scale (Prep-DM) to assess the patients' perception of how useful the educational tool is in preparing them to communicate with their practitioner at a consultation. It is a 10-item scale developed to evaluate decision processes relating to the preparation of patients for decision making and dialoguing with their practitioners.
Time frame: Immediately after the clinical encounter
Started Apr 2022 (actual). Primary completion is estimated for Feb 2027, 57 months after the start.
Of 47 non-industry observational studies under Spondylitis, Ankylosing, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 201. This study's planned 57 months is below that.
Counting every sponsor, half of 80 studies reached it within 47 months; a quarter within 27 and three quarters within 116.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.